Abstracts

ANTICHOLINERGIC DRUG USE IN PATIENTS ≥ 65 YEARS OLD IN THE SWISS HIV COHORT STUDY

Medications with anticholinergic (ACH) activity have been associated with neurocognitive impairment (NCI), particularly in elderly due to a reduced number of cholinergic receptors. People with HIV (PWH) are more likely to have NCI as they age. Additional risk factors include viral replication, chronic inflammation, antiretroviral therapy (ART) toxicity, higher rates of depression, and previous central nervous…

A RANDOMIZED TRIAL OF ADJUNCTIVE TELMISARTAN TO REDUCE CNS INFLAMMATION IN ACUTE HIV

Telmisartan is an angiotensin II receptor antagonist that inhibits inflammatory cytokines and macrophage activity. We hypothesized that initiation of antiretroviral therapy (ART) with adjunctive telmisartan in acute HIV infection (AHI) would reduce inflammation and immune activation and alter the pathogenesis of HIV within the central nervous system (CNS). 21 participants with AHI were randomized 2:1…

PROTEOMIC CHARACTERIZATION OF CSF EXTRACELLULAR VESICLES IN HIV PATIENTS

Extracellular vesicles (EVs) are nano-sized particles present in most body fluids including cerebrospinal fluid (CSF). Little is known about CSF EV proteins in HIV+ individuals. In this cross-sectional study, we characterized the CSF EV proteome in HIV+ subjects and its relationship to neuroinflammation, stress responses, and HIV-associated neurocognitive disorders (HAND). CSF EVs isolated from 20…

INFLAMMATORY MARKERS SHOW DYNAMIC CHANGES IN ACUTE HIV AND PREDICT COGNITIVE OUTCOMES

HIV-associated neurocognitive disorder (HAND) has been associated with elevated inflammatory markers in the peripheral blood and cerebrospinal fluid (CSF) in chronic HIV. We investigated the dynamics of viral load and inflammatory markers in CSF and plasma during acute HIV infection and their impact on longitudinal neurocognitive performance (NP) after antiretroviral therapy (ART) in Peru. MSM…

AGE-ASSOCIATED DEMENTIA AMONG OLDER PEOPLE WITH HIV IN THE US: A MODEL-BASED ANALYSIS

Approximately 25-30% of people with HIV (PWH) in the US (~300,000) are ≥55y and at risk for age-associated dementias (AAD), including Alzheimer’s disease and vascular dementias. We project the lifetime cumulative incidence and mortality associated with AAD among PWH in the US. We expanded the validated Cost-effectiveness of Preventing AIDS Complications (CEPAC) model to incorporate…